AAAAAA
Results: 1-25/45
Authors:
Gotto, AM
Farmer, JA
Citation: Am. Gotto et Ja. Farmer, Pleiotropic effects of statins: do they matter?, CURR OP LIP, 12(4), 2001, pp. 391-394
Authors:
Gotto, AM
Citation: Am. Gotto, How do we achieve optimal cardiovascular risk reduction?, CLIN CARD, 24(8), 2001, pp. 8-12
Authors:
Ridker, PM
Gotto, AM
Citation: Pm. Ridker et Am. Gotto, The antiinflammatory effects of statins. Reply, N ENG J MED, 345(16), 2001, pp. 1210-1211
Authors:
Ridker, PM
Rifai, N
Clearfield, M
Downs, JR
Weis, SE
Miles, JS
Gotto, AM
Citation: Pm. Ridker et al., Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events, N ENG J MED, 344(26), 2001, pp. 1959-1965
Authors:
Gotto, AM
Citation: Am. Gotto, Robert I. Levy 1937-2000 - In memoriam, J LIPID RES, 42(5), 2001, pp. 886-887
Authors:
Han, JH
Nicholson, AC
Zhou, XY
Feng, JW
Gotto, AM
Hajjar, DP
Citation: Jh. Han et al., Oxidized low density lipoprotein decreases macrophage expression of scavenger receptor B-I, J BIOL CHEM, 276(19), 2001, pp. 16567-16572
Authors:
Turban, S
Fuentes, F
Ferlic, L
Brugada, R
Gotto, AM
Ballantyne, CM
Marian, AJ
Citation: S. Turban et al., A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin, ATHEROSCLER, 154(3), 2001, pp. 633-640
Authors:
Lutucuta, S
Ballantyne, CM
Elghannam, H
Gotto, AM
Marian, AJ
Citation: S. Lutucuta et al., Novel polymorphisms in promoter region of ATP binding cassette transportergene and plasma lipids, severity, progression, and regression of coronary atherosclerosis and response to therapy, CIRCUL RES, 88(9), 2001, pp. 969-973
Authors:
Gotto, AM
Citation: Am. Gotto, Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease - A working group report, CIRCULATION, 103(17), 2001, pp. 2213-2218
Authors:
Gotto, AM
Citation: Am. Gotto, Primary prevention of coronary heart disease - Where do we go from here?, ARCH IN MED, 161(7), 2001, pp. 922-924
Authors:
Gotto, AM
Citation: Am. Gotto, Emerging perspectives on lipid management: International approaches and global challenges, AM J CARD, 88(8), 2001, pp. 876-881
Authors:
Gotto, AM
Citation: Am. Gotto, Current perspectives on identifying and managing hyperlipidemia - Introduction, AM J CARD, 88(4A), 2001, pp. 1F-1F
Authors:
Gotto, AM
Citation: Am. Gotto, Ongoing clinical trials of statins, AM J CARD, 88(4A), 2001, pp. 36F-40F
Authors:
Downs, JR
Clearfield, M
Tyroler, HA
Whitney, EJ
Kruyer, W
Langendorfer, A
Zagrebelsky, V
Weis, S
Shapiro, DR
Beere, PA
Gotto, AM
Citation: Jr. Downs et al., Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): Additional perspectives on tolerability of long-term treatment with lovastatin, AM J CARD, 87(9), 2001, pp. 1074-1079
Authors:
Gotto, AM
Olsson, AG
Citation: Am. Gotto et Ag. Olsson, A symposium: In Search of the Ideal Lipid-Lowering Agent - Introduction, AM J CARD, 87(5A), 2001, pp. 1B-1B
Authors:
Gotto, AM
Citation: Am. Gotto, Statin therapy: Where are we? Where do we go next?, AM J CARD, 87(5A), 2001, pp. 13B-18B
Authors:
Clearfield, M
Whitney, EJ
Weis, S
Downs, JR
Shapiro, DR
Stein, EA
Watson, DJ
Langendorfer, A
Beere, PA
Stamler, J
Gotto, AM
Citation: M. Clearfield et al., Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): baseline characteristics and comparison with USA population, J CARD RISK, 7(2), 2000, pp. 125-133
Authors:
Hunninghake, DB
McKenney, JM
Gotto, AM
Mehta, JL
Jones, PH
Citation: Db. Hunninghake et al., Achieving more aggressive low-density lipoprotein cholesterol lowering, AM J M CARE, 6(19), 2000, pp. S1008-S1016
Authors:
Elghannam, H
Tavackoli, S
Ferlic, L
Gotto, AM
Ballantyne, CM
Marian, AJ
Citation: H. Elghannam et al., A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy, J MOL MED-J, 78(10), 2000, pp. 562-568
Authors:
Ballantyne, CM
Herd, JA
Stein, EA
Ferlic, LL
Dunn, JK
Gotto, AM
Marian, AJ
Citation: Cm. Ballantyne et al., Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy, J AM COL C, 36(5), 2000, pp. 1572-1578
Authors:
Vaughan, CJ
Gotto, AM
Basson, CT
Citation: Cj. Vaughan et al., The evolving role of statins in the management of atherosclerosis, J AM COL C, 35(1), 2000, pp. 1-10
Authors:
Marian, AJ
Safavi, F
Ferlic, L
Dunn, JK
Gotto, AM
Ballantyne, CM
Citation: Aj. Marian et al., Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin - The lipoprotein and coronary atherosclerosis study, J AM COL C, 35(1), 2000, pp. 89-95
Authors:
Gotto, AM
Whitney, E
Stein, EA
Shapiro, DR
Clearfield, M
Weis, S
Jou, JY
Langendorfer, A
Beere, PA
Watson, DJ
Downs, JR
de Cani, JS
Citation: Am. Gotto et al., Application of the National Cholesterol Education Program and joint European treatment criteria and clinical benefit in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS), EUR HEART J, 21(19), 2000, pp. 1627-1633
Authors:
Feng, JW
Han, JH
Pearce, SFA
Silverstein, RL
Gotto, AM
Hajjar, DP
Nicholson, AC
Citation: Jw. Feng et al., Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-gamma, J LIPID RES, 41(5), 2000, pp. 688-696
Authors:
Han, JH
Hajjar, DP
Tauras, JM
Feng, JW
Gotto, AM
Nicholson, AC
Citation: Jh. Han et al., Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-gamma, J BIOL CHEM, 275(2), 2000, pp. 1241-1246